FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average but	urden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hayden Michael R					2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
					. []									'					· I
(Last) (First) (Middle) 2855 GAZELLE COURT					3. Date of Earliest Transaction (Month/Day/Year) 10/17/2022										Officer (give title below)		Other (below)	specify	
(Street)	BAD C.	A	92010		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	e) <mark>X</mark> Form f	lividual or Joint/Group Fili Form filed by One Re Form filed by More th			n
(City)	(S	tate)	(Zip)												Persor				9
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,			Transaction Dispose Code (Instr. 5)			rities Acquired (A) or ad Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A (D	or	Price	Transaction(s) (Instr. 3 and 4)				(111341. 4)
Common Stock 10/17/				7/2022	/2022		M ⁽¹⁾		1,777	1,777 ⁽¹⁾ A		\$0.0	23	23,109		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		Transaction Code (Instr.		of E		5. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisab		Expiration Date	Title	OI N	umber					
Restricted Stock Unit	\$0.0(2)	10/17/2022			M			1,777	(3)		(3)	Commo	n 1	1,777	\$0.0	7,110)	D	

Explanation of Responses:

- 1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
- 2. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- 3. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

By: Patrick R. O'Neil, attorney-10/18/2022 in-fact For: Michael R. Hayden

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.